html contador
No icon


COVID-19, Russia registers second vaccine

Russian President Vladimir Putin announced the registration of the second vaccine against COVID-19, named EpiVacCorona, developed by the Véktor State Research Center for Virology and Biotechnology.

Putin stressed that, as with Sputnik-V, Russia will promote the second vaccine abroad and advocated that drug production be concentrated in those countries where it will be commercialized. He stressed that Russian coronavirus vaccines must first meet all the needs of the domestic market and reach as many pharmacies as possible.

"From what I know, we have a third vaccine underway from the Chumakov center of the Russian Academy of Sciences," he added, referring to the one that will enter its second phase of testing on October 19.

The Government announced that 40,000 volunteers will participate in the clinical analyzes of the second Russian vaccine in which 150 people over 60 will participate.

"The appearance of the second vaccine increases the chances of vaccination among the population and, therefore, brings us closer to stabilizing and overcoming the problem of COVID-19 infection," explained Deputy Prime Minister Tatiana Gólikova. She announced that the first batch of 60,000 doses will be produced shortly.

Gólikova admitted that she and Russian Chief Health Officer Anna Popova were vaccinated with EpiVacCorona and have not experienced any side effects. "All the volunteers who took part in the first and second phases did not experience a temperature increase," he stressed.

The first Russian vaccine, Sputnik V, was registered on August 11 and is currently in phase III trials, the first results of which are expected in October or November.

According to the authorities, Russia registered 14,231 cases of COVID-19 in the last 24 hours, a figure that follows the upward trend in infections in recent weeks. In total, since the beginning of the pandemic, 1,340,409 cases have been detected in Russia, of which 23,205 have died after adding another 239 deaths.


Comment As:

Comment (0)